The past two years have seen a wide array of scientific discovery and legal issues that affect the development, production, distribution and use of pharmaceuticals, biotechnology products and medical devices as well as ways of providing health services. The field facilitated innovation and regulated risks at record speed. In a conference spanning two days, industry speakers and other legal experts will try to sum up key developments featuring dynamic roundtable sessions, as well as panels covering the following topics across the different sectors of the healthcare and life sciences industry.
Featured Session:
Introduction of the moot trial
The moot trial will be based on a hypothetical case scenario about the infringement of patents rights and know-how in the context of a supply agreement for the manufacture and distribution of COVID-19 treatments worldwide. The discussion will involve relevant legal, contractual and statutory issues in life sciences disputes, as well as procedural considerations particular to international arbitration and mediation proceedings and crossborder provisional measures and their enforcement. Claimant and respondent counsel teams will present their positions and legal arguments in a mock hearing, and dispute resolution experts will mediate and arbitrate the dispute in accordance with recognized legal standards and international practices. Availability of provisional or protective measures in aid of arbitration proceedings will also be discussed.
Arbitral tribunal:
Featured JAMS Speaker:
Sessions include:
- Three keynote speeches:
- BioNTech on the supply of vaccines and intellectual property stakes to tackle the Covid-19 virus and other diseases
- The French Health Data Hub on the development of Al & Health and the sharing of health data in support of innovation
- Novartis on patent infowars
- Moot court on vaccine liability in Covid-19
- 15 roundtables of current hot topics
- New investment models in life sciences companies
- Compulsory licensing or co-opetition arrangments: a new way to access medicines and vaccines?
- International transparency and cooperation for pricing / reimbursement
- Beyond data protection: wider legal and ethical considerations around data collection and use
- Will artificial intelligence replace physicians? AI reshuffles the cards by reallocating roles, risks and liabilities
Featured Session:
Introduction of the moot trial
The moot trial will be based on a hypothetical case scenario about the infringement of patents rights and know-how in the context of a supply agreement for the manufacture and distribution of COVID-19 treatments worldwide. The discussion will involve relevant legal, contractual and statutory issues in life sciences disputes, as well as procedural considerations particular to international arbitration and mediation proceedings and crossborder provisional measures and their enforcement. Claimant and respondent counsel teams will present their positions and legal arguments in a mock hearing, and dispute resolution experts will mediate and arbitrate the dispute in accordance with recognized legal standards and international practices. Availability of provisional or protective measures in aid of arbitration proceedings will also be discussed.
-
Lorenza Ferrari Pestalozzi, Zurich
- Alejandro Luna Fandiño Olivares, Mexico City; Co-Chair, IBA Intellectual Property and Entertainment Law Committee
- Daniel Reich Gaillard Banifatemi Shelbaya, New York
Arbitral tribunal:
- Philipp Groz Schellenberg Wittmer, Zurich
- Dr Pierrick Le Goff De Gaulle Fleurance & Associés, Paris
- Daniel Reich Gaillard Banifatemi Shelbaya, New York
Mediator:
- Conna A Weiner JAMS, Boston, Massachusetts
Featured JAMS Speaker:
- Conna A. Weiner, Esq., FCIArb, Mediator, Arbitrator and Referee/Special Master - JAMS Boston
Featured People
- Business Commercial
- Employment Law
- Health Care
- Intellectual Property
- International & Cross-Border
- Life Sciences
- Pharmaceuticals & Mass Torts